Preparation and initial characterization of biodegradable particles containing gadolinium-DTPA contrast agent for enhanced MRI.
Accurate imaging of atherosclerosis is a growing necessity for timely treatment of the disease. Magnetic resonance imaging (MRI) is a promising technique for plaque imaging. The goal of this study was to create polymeric particles of a small size with high loading of diethylenetriaminepentaacetic acid gadolinium (III) (Gd-DTPA) and demonstrate their usefulness for MRI. A water-in-oil-in-oil double emulsion solvent evaporation technique was used to encapsulate the MRI agent in a poly(lactide-co-glycolide) (PLGA) or polylactide-poly(ethylene glycol) (PLA-PEG) particle for the purpose of concentrating the agent at an imaging site. PLGA particles with two separate average sizes of 1.83 microm and 920 nm, and PLA-PEG particles with a mean diameter of 952 nm were created. Loading of up to 30 wt % Gd-DTPA was achieved, and in vitro release occurred over 5 h. PLGA particles had highly negative zeta potentials, whereas the particles incorporating PEG had zeta potentials closer to neutral. Cytotoxicity of the particles on human umbilical vein endothelial cells (HUVEC) was shown to be minimal. The ability of the polymeric contrast agent formulation to create contrast was similar to that of Gd-DTPA alone. These results demonstrate the possible utility of the contrast agent-loaded polymeric particles for plaque detection with MRI.
Doiron
Amber L
AL
Department of Biomedical Engineering, University of Texas, Austin, TX 78712, USA.
Chu
Kevin
K
Ali
Adeel
A
Brannon-Peppas
Lisa
L
D050197:Atherosclerosis / Q000175:diagnosis*; D002460:Cell Line; D003287:Contrast Media / Q000633:toxicity; D042783:Endothelial Cells / Q000187:drug effects; D019786:Gadolinium DTPA; D006801:Humans; D019344:Lactic Acid / Q000138:chemical synthesis*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008855:Microscopy, Electron, Scanning; D010316:Particle Size; D011100:Polyglycolic Acid / Q000138:chemical synthesis*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer
D003287:Contrast Media; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D019786:Gadolinium DTPA
Trends Cardiovasc Med. 2005 Jan;15(1):17-24
15795159
Magn Reson Med. 2006 May;55(5):1023-9
16586449
Circ Res. 2001 Aug 17;89(4):305-16
11509446
Invest Radiol. 1993 Sep;28(9):789-95
8225882
Circulation. 1988 Nov;78(5 Pt 1):1157-66
3180375
Int J Pharm. 2006 Jan 3;307(1):93-102
16303268
Magn Reson Med. 2005 Mar;53(3):614-20
15723408
Circulation. 2003 Nov 4;108(18):2270-4
14557370
Pharm Res. 1999 Dec;16(12):1830-5
10644070
Ann Biomed Eng. 2005 Feb;33(2):179-90
15771271
Magn Reson Med. 2004 Jun;51(6):1265-71
15170848
Magn Reson Imaging. 2004 Jul;22(6):843-50
15234453
J Microencapsul. 2003 May-Jun;20(3):349-59
12881115
J Am Coll Cardiol. 1988 Jul;12(1):56-62
3379219
Adv Drug Deliv Rev. 2004 Sep 22;56(11):1649-59
15350294
Nat Rev Drug Discov. 2004 Nov;3(11):913-25
15520814
N Engl J Med. 1987 May 28;316(22):1371-5
3574413
Circulation. 2001 Sep 11;104(11):1280-5
11551880
Biomaterials. 2000 Dec;21(23):2475-90
11055295
J Biomed Mater Res. 1998 Oct;42(1):45-54
9740006
Circulation. 1986 Apr;73(4):653-61
3948368
Eur J Pharm Sci. 1999 May;8(2):99-107
10210732
Circulation. 2007 Feb 6;115(5):e69-171
17194875
Magn Reson Med. 1999 Oct;42(4):762-71
10502766
Circulation. 2002 Sep 10;106(11):1368-73
12221054
Circulation. 1995 Sep 1;92(5):1355-74
7648691
Magn Reson Med. 2006 Sep;56(3):601-10
16902977
Pharm Res. 1999 Jun;16(6):859-66
10397606
Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):961-6
17215360
Circulation. 1994 May;89(5):2462-78
8181179